>
Cell MedX logo

CMXC - Cell MedX Share Price

$0.207 0.0  3.6%

Last Trade - 15/10/21

Sector
Healthcare
Size
Micro Cap
Market Cap £9.36m
Enterprise Value £9.59m
Revenue £4.92k
Position in Universe 6751st / 7247
Bullish
Bearish
Unlock CMXC Revenue
Momentum
Relative Strength (%)
1m -6.73%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -51.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st May 2016 2017 2018 2019 2020 2021 2022E 2023E CAGR / Avg
0.037 0.006 0.000 0.000 0.096 0.007 -28.7%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 May 2021, Cell MedXCorp revenues decreased 93% to $7K. Net loss decreased 17%to $911K. Revenues reflect Distribution rights decreasefrom $76K to $0K, Sales decrease of 66% to $7K. Lower netloss reflects General and administrative expenses decreaseof 53% to $186K (expense), Research and development costsdecrease of 42% to $230K (expense), Loss on reacquisitionof distribution ri decrease from $102K (expense) to $0K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CMXC Revenue Unlock CMXC Revenue

Net Income

CMXC Net Income Unlock CMXC Revenue

Normalised EPS

CMXC Normalised EPS Unlock CMXC Revenue

PE Ratio Range

CMXC PE Ratio Range Unlock CMXC Revenue

Dividend Yield Range

CMXC Dividend Yield Range Unlock CMXC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CMXC EPS Forecasts Unlock CMXC Revenue
Profile Summary

Cell MedX Corp. is a development-stage company focused on the discovery, development and commercialization of therapeutic products for patients with diseases, such as diabetes, by developing technologies to help manage the illness and related complications. The Company, through its subsidiary, Avyonce Cosmedics Inc. (Avyonce), is engaged in reselling and marketing spa technology and equipment to the beauty and wellness industry. Avyonce is involved in carrying out observational studies using eBalance Technology. The eBalance Technology is used for the use of micro currents for the treatment of diabetes and related ailments. Avyonce also provides continuing education to the estheticians and healthcare professionals in the field of medical aesthetics. The Company is engaged in developing a family of devices based on the eBalance Technology.

Directors
Last Annual May 31st, 2021
Last Interim May 31st, 2021
Incorporated March 19, 2010
Public Since March 11, 2013
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Pink Sheets on Nasdaq
Shares in Issue 62,073,064
Free Float (0.0%)
Eligible for
× ISAs
SIPPs
CMXC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CMXC
Upcoming Events for CMXC
Frequently Asked Questions for Cell MedX
What is the Cell MedX share price?

As of 15/10/21, shares in Cell MedX are trading at $0.207, giving the company a market capitalisation of £9.36m. This share price information is delayed by 15 minutes.

How has the Cell MedX share price performed this year?

Shares in Cell MedX are currently trading at $0.207 and the price has moved by -53.94% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cell MedX price has moved by -63.31% over the past year.

What are the analyst and broker recommendations for Cell MedX?

There are no analysts currently covering Cell MedX.

When will Cell MedX next release its financial results?

Cell MedX is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-05-31
What is the Cell MedX dividend yield?

Cell MedX does not currently pay a dividend.

Does Cell MedX pay a dividend?

Cell MedX does not currently pay a dividend.

When does Cell MedX next pay dividends?

Cell MedX does not currently pay a dividend.

How do I buy Cell MedX shares?

To buy shares in Cell MedX you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cell MedX?

Shares in Cell MedX are currently trading at $0.207, giving the company a market capitalisation of £9.36m.

Where are Cell MedX shares listed? Where are Cell MedX shares listed?

Here are the trading details for Cell MedX:

Country of listing: United States
Exchange: PNK
Ticker Symbol: CMXC
What kind of share is Cell MedX?

Based on an overall assessment of its quality, value and momentum, Cell MedX is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Cell MedX share price forecast 2021?

We were not able to load any forecast data for Cell MedX.

How can I tell whether the Cell MedX share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cell MedX. Over the past six months, the relative strength of its shares against the market has been -14.1%. At the current price of $0.207, shares in Cell MedX are trading at -20.17% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cell MedX PE Ratio?

We were not able to find PE ratio data for Cell MedX.

Who are the key directors of Cell MedX?

Cell MedX's management team is headed by:

Frank McEnulty - CEO
Bradley Hargreaves - VOP
Yanika Silina - CFO
George Adams - IND
Joao da Costa - COO
Who are the major shareholders of Cell MedX?

Here are the top five shareholders of Cell MedX based on the size of their shareholding:

Jeffs (Richard Norman) Individual Investor
Percentage owned: 18.95% (11.3m shares)
Arnett (Jean M) Individual Investor
Percentage owned: 10.52% (6.25m shares)
Hargreaves (Bradley S) Individual Investor
Percentage owned: 9.35% (5.55m shares)
Jeffs (Susan) Individual Investor
Percentage owned: 4.53% (2.69m shares)
Tradex Capital Corp Corporation
Percentage owned: 3.39% (2.01m shares)
Similar to CMXC
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.